Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma.

ABSTRACT: Pancreatic ductal adenocarcinoma is traditionally characterized as a glycolytic tumor. However, the extent and clinical relevance of its metabolic heterogeneity remain poorly understood. In this study, we investigated whether glycolytic activity follows a consistent expression pattern across pancreatic ductal adenocarcinoma patients and explored how metabolic diversity influences therapeutic responses. Using spatial transcriptomics of ex vivo primary human pancreatic ductal adenocarcinoma specimens, along with single-cell and bulk RNA sequencing, we mapped glycolytic heterogeneity within the tumor microenvironment. Patient-derived cell models representing distinct glycolytic phenotypes were employed to assess metabolic profiles and responses to glycolytic pathway inhibition. A multiomics a

SUBMITTER: Chianese U 

PROVIDER: S-EPMC12816621 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature